Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 4408-4419

  López Soto, Alejandro ^a   Huergo Zapico, Leticia ^a   Galvan, José Alberto ^a   Rodrigo, Luis ^b   De Herreros, Antonio García ^c   Astudillo, Aurora ^a,b   Gonzalez, Segundo ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 CHAIN RELATED MOLECULE A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 CHAIN RELATED MOLECULE B; MAMMALIAN TARGET OF RAPAMYCIN; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL1; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR CELL LINE; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; COLORECTAL NEOPLASMS; EPITHELIUM; HELA CELLS; HEP G2 CELLS; HT29 CELLS; HUMANS; IMMUNOPHENOTYPING; MESODERM; MICE; NEOPLASM INVASIVENESS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 84875970630     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202950     Document Type: Article

References (39)

1. Gavert, N., and A. Ben-Ze'ev. 2008. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol. Med. 14: 199-209.
2. Polyak, K., and R. A. Weinberg. 2009. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9: 265-273.
3. Batlle, E., E. Sancho, C. Francí, D. Domínguez, M. Monfar, J. Baulida, and A. García De Herreros. 2000. The transcription factor snail is a repressor of Ecadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2: 84-89.
4. Cano, A., M. A. Pérez-Moreno, I. Rodrigo, A. Locascio, M. J. Blanco, M. G. del Barrio, F. Portillo, and M. A. Nieto. 2000. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2: 76-83.
5. Bachelder, R. E., S. O. Yoon, C. Franci, A. G. de Herreros, and A. M. Mercurio. 2005. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J. Cell Biol. 168: 29-33.
6. Zhou, B. P., J. Deng, W. Xia, J. Xu, Y. M. Li, M. Gunduz, and M. C. Hung. 2004. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6: 931-940.
7. Shi, Y., and J. Massagué. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
8. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
9. López-Larrea, C., B. Suárez-Alvarez, A. López-Soto, A. López-Vázquez, and S. Gonzalez. 2008. The NKG2D receptor: sensing stressed cells. Trends Mol. Med. 14: 179-189.
10. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. M. Greenberg, and D. H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
11. Bahram, S., M. Bresnahan, D. E. Geraghty, and T. Spies. 1994. A second lineage of mammalian major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 91: 6259-6263.
12. Cosman, D., J. Müllberg, C. L. Sutherland, W. Chin, R. Armitage, W. Fanslow, M. Kubin, and N. J. Chalupny. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133.
13. González, S., A. López-Soto, B. Suarez-Alvarez, A. López-Vázquez, and C. López-Larrea. 2008. NKG2D ligands: key targets of the immune response. Trends Immunol. 29: 397-403.
14. Smyth, M. J., J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama, and Y. Hayakawa. 2005. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202: 583-588.
15. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190.
16. López-Soto, A., A. R. Folgueras, E. Seto, and S. Gonzalez. 2009. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 28: 2370-2382.
17. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
18. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
19. Sato, E., S. H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A. A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al. 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102: 18538-18543.
20. López-Soto, A., A. Quiñones-Lombraña, R. López-Arbesú, C. López-Larrea, and S. González. 2006. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J. Biol. Chem. 281: 30419-30430.
21. Rodríguez-Rodero, S., S. González, L. Rodrigo, J. L. Fernández-Morera, J. Martínez-Borra, A. López- Vázquez, and C. López-Larrea. 2007. Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1. Eur. J. Immunol. 37: 1938-1953.
22. Salih, H. R., H. Antropius, F. Gieseke, S. Z. Lutz, L. Kanz, H. G. Rammensee, and A. Steinle. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396.
23. Zavadil, J., and E. P. Böttinger. 2005. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774.
24. Calon, A., E. Espinet, S. Palomo-Ponce, D. V. Tauriello, M. Iglesias, M. V. Céspedes, M. Sevillano, C. Nadal, P. Jung, X. H. Zhang, et al. 2012. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22: 571-584.
25. Venkataraman, G. M., D. Suciu, V. Groh, J. M. Boss, and T. Spies. 2007. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 178: 961-969.
26. Blume, S. W., R. C. Snyder, R. Ray, S. Thomas, C. A. Koller, and D. M. Miller. 1991. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 88: 1613-1621.
27. Lamouille, S., and R. Derynck. 2007. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol. 178: 437-451.
28. Boissel, N., D. Rea, V. Tieng, N. Dulphy, M. Brun, J. M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F. X. Mahon, et al. 2006. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol. 176: 5108-5116.
29. Brown, E. J., M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith, W. S. Lane, and S. L. Schreiber. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369: 756-758.
30. Watson, N. F., I. Spendlove, Z. Madjd, R. McGilvray, A. R. Green, I. O. Ellis, J. H. Scholefield, and L. G. Durrant. 2006. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 118: 1445-1452.
31. Skov, S., M. T. Pedersen, L. Andresen, P. T. Straten, A. Woetmann, and N. Odum. 2005. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65: 11136-11145.
32. Eisele, G., J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese. 2006. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129: 2416-2425.
33. Lee, J. C., K. M. Lee, D. W. Kim, and D. S. Heo. 2004. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172: 7335-7340.
34. Friese, M. A., J. Wischhusen, W. Wick, M. Weiler, G. Eisele, A. Steinle, and M. Weller. 2004. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64: 7596-7603.
35. Venkov, C., D. Plieth, T. Ni, A. Karmaker, A. Bian, A. L. George, Jr., and E. G. Neilson. 2011. Transcriptional networks in epithelial-mesenchymal transition. PLoS ONE 6: e25354.
36. Kudo-Saito, C., H. Shirako, T. Takeuchi, and Y. Kawakami. 2009. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15: 195-206.
37. Ito, M., T. Maruyama, N. Saito, S. Koganei, K. Yamamoto, and N. Matsumoto. 2006. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J. Exp. Med. 203: 289-295.
38. Knutson, K. L., H. Lu, B. Stone, J. M. Reiman, M. D. Behrens, C. M. Prosperi, E. A. Gad, A. Smorlesi, and M. L. Disis. 2006. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J. Immunol. 177: 1526-1533.
39. Kmieciak, M., K. L. Knutson, C. I. Dumur, and M. H. Manjili. 2007. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cellmediated anti-tumor immune responses. Eur. J. Immunol. 37: 675-685.